ORZORA: OPEN-LABEL PHASE IV TRIAL OF OLAPARIB IN PATIENTS WITH BRCA-MUTATED OVARIAN CANCER

被引：0
|
作者：
Pignata, S. [1 ]
Lewis, J. [2 ]
Tchakov, I. [2 ]
Robertson, J. D. [3 ]
Morris, T. [3 ]
Jayawardene, D. [4 ]
Tyczynski, J. E. [4 ]
Hodgson, D. R. [3 ]
Mills, J. [3 ]
Di Maio, M. [5 ]
机构：
[1] Natl Canc Inst Naples, Urogynecol Dept, Naples, Italy
[2] AstraZeneca, Global Med Affairs, Cambridge, England
[3] AstraZeneca, Global Clin Dev, Macclesfield, Cheshire, England
[4] AstraZeneca, Global Medicines Dev, Gaithersburg, MD USA
[5] Univ Turin, Dept Oncol, Turin, Italy
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-0933
引用
收藏
页码：1469 / 1470
页数：2
相关论文
共 50 条
  • [21] Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
    Lieberman, Howard B.
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 418 - 420
  • [22] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PERU
    Torres Toala, F. G.
    Solorzano, J.
    Baldi, J.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [23] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PANAMA
    Torres Toala, F. G.
    Solorzano, J.
    Baldi, J.
    Castillo-Fernandez, O.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [24] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [25] Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
    Velev, Maud
    Puszkiel, Alicja
    Blanchet, Benoit
    de Percin, Sixtine
    Delanoy, Nicolas
    Medioni, Jacques
    Gervais, Claire
    Balakirouchenane, David
    Khoudour, Nihel
    Pautier, Patricia
    Leary, Alexandra
    Ajgal, Zahra
    Hirsch, Laure
    Goldwasser, Francois
    Alexandre, Jerome
    Beinse, Guillaume
    PHARMACEUTICALS, 2021, 14 (08)
  • [26] Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
    Le, Dan
    Gelmon, Karen A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (09) : 833 - 839
  • [27] Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
    Nicoletto, Maria Ornella
    Baldoni, Alessandra
    Cavallin, Francesco
    Grego, Andrea
    Falci, Cristina
    Nardin, Margherita
    Mammano, Enzo
    Lai, Eleonora
    Torri, Valter
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [28] Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain
    Moya-Alarcon, Carlota
    Gonzalez-Dominguez, Almudena
    Ivanova-Markova, Yoana
    Gimeno-Ballester, Vicente
    Barretina-Ginesta, Maria-Pilar
    Alejandro Perez-Fidalgo, Jose
    Redondo, Andres
    GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 406 - 414
  • [29] MAINTENANCE TREATMENT WITH OLAPARIB IN BRCA-MUTATED HIGH GRADE SEROUS OVARIAN CANCER (HGSOC): OUR EXPERIENCE IN A CASE REPORT
    Mainella, A.
    Giacomi, N.
    Marmissolle, F.
    Vigo, S.
    Price, P.
    Sansano, M.
    Lujan, M. L.
    Zapata Caamano, G.
    Dominguez, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1585 - 1585
  • [30] BUDGET IMPACT ANALYSIS FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN COSTA RICA
    Torres Toala, F. G.
    Solorzano, J.
    Baldi, J.
    Landaverde, D.
    Gonzalez, I
    VALUE IN HEALTH, 2018, 21 : S21 - S21
12345